Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma

Inclusion Criteria: * age≥18 years * PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDR-related complications such as nonclearing VH, macula-involving or macula-threatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions * NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle) Exclusion Criteria: * intraoperative use of long-acting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy * previous intravitreal injection of ranibizumab or bevacizumab in either eye * previous intravitreal corticosteroids injection in either eye * pregnancy or current oral contraceptive intake * usage of clopidogrel bisulfate or coumadin * uncontrolled hypertension and cardiac disease * uncontrolled renal or liver disease